Neopharma launches its four new products

ABU DHABI — Abu Dhabi based pharmaceutical manufacturer Neopharma has diversified into new segments with the launch of four new products to cater to the needs of the UAE as well enlarging exports market.

By A Staff Reporter

Published: Mon 21 Aug 2006, 9:48 AM

Last updated: Sat 4 Apr 2015, 2:19 PM

The company, known for introducing new products in

quick succession, is focusing on strengthening its antibiotic portfolio. With key antibiotics such as co-amoxyclav, clarithromycin and ciprofloxacin already in the market, the introduction of cefuroxime axetil and doxycycline will witness the company's foray into the cephalosporins and tetracycline antibiotics segments.

The launch of omeprazole paves the way for Neopharma's entry into the gastroenterology segment.

The company has extended its presence in the respiratory medicine segment with the launch of one more variation of cough syrup.

Since last two years, the company has introduced more than 57 products, thus taking local manufacturing prowess to newer heights.

Local pharmaceutical manufacturing comes with its own set of advantages.

While on one hand domestic manufacturing capabilities enhance self sufficiency in popular therapy segments, on the other, producing drugs locally help avoid import delays and curtail more serious problems such as fakes or duplicates in the market.

More news from Business